Spectrum Pharmaceuticals, Inc.
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
0
Ending by 2030
Jan 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use (US 10,350,240) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Crystalline Forms of a Quinazoline Compound and Its Hydrochloride Salts (US 11,883,402) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Oct 12, 2027The maintenance fee for Treatment of Primary and Metastatic Carcinoma (US 9,308,235) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,273,716 | Use of LHRH antagonists for intermittent treatments In force · From the USPTO record | In force | From the USPTO record | |
| US 11,406,663 | Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use In force · High confidence | In force | High confidence | |
| US 8,961,917 | Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use In force · High confidence | In force | High confidence | |
| US 10,350,240 | Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use In force · High confidence | In force | High confidence | |
| US 9,308,235 | Treatment of Primary and Metastatic Carcinoma In force · High confidence | In force | High confidence | |
| US 12,773,459 | Methods of Treatment Using G-Csf Protein Complex In force · Medium confidence | In force | Medium confidence | |
| US 11,883,402 | Crystalline Forms of a Quinazoline Compound and Its Hydrochloride Salts In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 11 patents in force now held by others · 17 lapsed for an unpaid fee · 31 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 20 abandoned · 2 no status recorded